“We respectfully disagree with the court’s decision regarding our development of the iPlatform and communications with Auris regarding soft tissue ablation,” a Johnson & Johnson spokesperson said. “Fundamentally, the court viewed our commercially reasonable contract as imposing a commercially unreasonable obligation. We are reviewing the decision and assessing our options for appeal.”
The spokesperson noted the decision pertains only to the Auris merger and has no bearing on its current robotics program or the anticipated release of its Ottava surgical robotics system.